Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,206 questions in 117 reviews · Common Mental Disorders
current versionsNo studies 387 · 17.5%Ungraded 111 · 5%Very low 635 · 28.8%Low 568 · 25.7%Moderate 449 · 20.4%High 56 · 2.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fluoxetine vs escitalopram Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.17 [0.64, 2.12] | 2 studies · 578 participants | Moderate |
Fluoxetine vs fluvoxamine Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.95 [0.52, 1.74] | 1 study · 177 participants | Low |
Fluoxetine vs fluvoxamine Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Fluoxetine vs fluvoxamine Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 71 [0.36, 1.37] | 2 studies · 284 participants | Moderate |
Fluoxetine vs fluvoxamine Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Fluoxetine vs fluvoxamine Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.04 [0.14, 7.71] | 1 study · 100 participants | Low |
Fluoxetine vs hypericum Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.98 [0.55, 1.73] | 6 studies · 717 participants | Moderate |
Fluoxetine vs hypericum Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 5 studies · 648 participants | Moderate |
Fluoxetine vs hypericum Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.04 | 5 studies · 679 participants | Moderate |
Fluoxetine vs hypericum Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 4.7 [0.22, 99.39] | 2 studies · 401 participants | Moderate |
Fluoxetine vs ABT‐200 Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Fluoxetine vs hypericum Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.21 [0.56, 2.64] | 5 studies · 679 participants | Moderate |
Fluoxetine vs maprotiline Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.95 [0.91, 4.18] | 2 studies · 163 participants | Moderate |
Fluoxetine vs maprotiline Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 5 studies · 433 participants | Moderate |
Fluoxetine vs maprotiline Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.75 [0.9, 3.41] | 4 studies · 351 participants | Moderate |
Fluoxetine vs maprotiline Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.53 [0.15, 1.93] | 3 studies · 209 participants | Moderate |
Fluoxetine vs maprotiline Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 2.54 [0.33, 19.9] | 3 studies · 209 participants | Moderate |
Fluoxetine vs mianserin Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.8 [0.27, 2.38] | 1 study · 53 participants | Very low |
Fluoxetine vs mianserin Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 3 studies · 128 participants | Moderate |
Fluoxetine vs mianserin Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.63 [0.18, 2.25] | 2 studies · 93 participants | Moderate |
Fluoxetine vs mianserin Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 2.27 [0.38, 13.63] | 1 study · 53 participants | Very low |
Fluoxetine vs ABT‐200 Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 1 study · 141 participants | Low |
Fluoxetine vs mianserin Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.05 [0.23, 4.7] | 1 study · 53 participants | Very low |
Fluoxetine vs milnacipran Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.2 [0.78, 1.84] | 2 studies · 370 participants | Moderate |
Fluoxetine vs milnacipran Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 2 studies · 213 participants | Moderate |
Fluoxetine vs milnacipran Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.98 [0.68, 1.42] | 3 studies · 560 participants | Moderate |
Fluoxetine vs milnacipran Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.25 [0.68, 2.3] | 3 studies · 560 participants | Moderate |
Fluoxetine vs milnacipran Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.5 [0.81, 2.76] | 3 studies · 560 participants | Moderate |
Fluoxetine vs mirtazapine Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.46 [1.04, 2.04] | 4 studies · 600 participants | Moderate |
Fluoxetine vs mirtazapine Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 1 study · 31 participants | Very low |
Fluoxetine vs mirtazapine Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.9 [0.55, 1.47] | 3 studies · 301 participants | Moderate |
Fluoxetine vs mirtazapine Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.45 [0.71, 2.96] | 4 studies · 600 participants | Moderate |
Fluoxetine vs ABT‐200 Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.18 [0.08, 0.39] | 1 study · 144 participants | Low |
Fluoxetine vs mirtazapine Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.95 [0.55, 1.64] | 4 studies · 600 participants | Moderate |
Fluoxetine vs moclobemide Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.27 [0.92, 1.75] | 7 studies · 721 participants | Moderate |
Fluoxetine vs moclobemide Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 6 studies · 540 participants | Moderate |
Fluoxetine vs moclobemide Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.01 [0.7, 1.45] | 7 studies · 721 participants | Moderate |
Fluoxetine vs moclobemide Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.7 [0.32, 1.56] | 6 studies · 679 participants | Moderate |
Fluoxetine vs moclobemide Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.07 [0.64, 1.8] | 7 studies · 721 participants | Moderate |
Fluoxetine vs nefazodone Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Fluoxetine vs nefazodone Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 4 studies · 271 participants | Moderate |
Fluoxetine vs nefazodone Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.54 [0.22, 1.31] | 3 studies · 161 participants | Moderate |
Fluoxetine vs nefazodone Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.71 [0.05, 10.71] | 3 studies · 161 participants | Moderate |
Fluoxetine vs ABT‐200 Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.24 [0.03, 2.2] | 1 study · 144 participants | Low |
Fluoxetine vs nefazodone Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.76 [0.32, 1.81] | 4 studies · 286 participants | Moderate |
Fluoxetine vs paroxetine Failure to respond (reduction ≥ 50% on HDRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 1.23 [0.93, 1.65] | 9 studies · 1574 participants | Moderate |
Fluoxetine vs paroxetine Endpoint score (HDRS or MADRS) · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | no estimate extracted | 11 studies · 2061 participants | Moderate |
Fluoxetine vs paroxetine Failure to complete ‐ total ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.98 [0.81, 1.2] | 10 studies · 1848 participants | Moderate |
Fluoxetine vs paroxetine Failure to complete ‐ inefficacy ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.75 [0.41, 1.39] | 4 studies · 1005 participants | Moderate |
Fluoxetine vs paroxetine Failure to complete ‐ side effects ‐ · patients with depression Fluoxetine versus other types of pharmacotherapy for depression (2013) · Cochrane | OR 0.85 [0.62, 1.16] | 9 studies · 1509 participants | Moderate |